Bladder Cancer – MK3475-057 Study (Clinical Trial):
The MK-3475-057 study is a Phase II Clinical Trial for Bladder Cancer. This trial targets patients with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy.
Eligible patients must have first received an adequate course of BCG therapy. This defined as, at least 5 instillations of induction BCG and an overall of at least 7 instillations of BCG within 9 months.
For patients to be unresponsive to BCG, they must have persistent high risk NMIBC at 6 months (±4 weeks) after adequate BCG or recurrent high risk NMIBC within 9 months of the last BCG instillation despite having received adequate BCG.
Furthermore, an eligible patient’s most recent cystoscopy must have High Grade Ta or any Grade T1 without CIS.
For further information please contact:
|Dr Sanjeev Sewak||Aimee Joost|
|Phone: (03) 9781 5244||Email: email@example.com|
|Phone: (03) 9781 5244|